Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies
Patent Information
- Application Number
- JP2024127744
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-06-18
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2039-06-18
Smart Images

Figure 2024156872000003 
Figure 2024156872000004 
Figure 2024156872000005
Abstract
Description
[Technical field]
[0001] This application claims priority to U.S. Provisional Patent Application No. 62 / 686,522, filed June 18, 2018, which is incorporated herein by reference in its entirety. This invention was made with Government support under AR070604 awarded by the National Institutes of Health. The Government has certain rights in this invention.
[0002] Incorporation by Reference of Electronically Submitted Materials This application contains a sequence listing in computer readable form, which is incorporated herein by reference in its entirety as a separate part of this disclosure, and is identified as Filename: 53147A_Seqlisting.txt, Size: 125,439 bytes, Created: June 18, 2019.
[0003] Products and methods are provided for treating dystroglycanopathy and laminin-deficient muscular dystrophies. In this method, a protein containing a linker domain, such as the heparin-binding domain of heparin-binding epidermal growth factor-like growth factor (HBEGF), is delivered to the patient. The linker protein serves to target the transgene to the extracellular matrix (ECM) of muscle cells. [Background technology]
[0004] Muscular dystrophies (MD) are a group of genetic disorders characterized by progressive weakening and degeneration of the skeletal muscles that control movement. Some forms of MD have an onset in infancy or childhood, whereas others may not appear until middle age or later. The disorders differ in the distribution and degree of muscle weakness (some forms of MD also affect the heart muscle), age at onset, rate of progression, and mode of inheritance.
[0005] Congenital muscular dystrophies (CMDs) represent a group of MDs in which loss of structural components of muscle results in neonatal hypotonia and progressive skeletal muscle weakness. These disorders are often associated with significant extramuscular complications, including impaired brain and eye development, cognitive impairment, seizures, and respiratory and cardiac anomalies, and require regular medical management by a multidisciplinary team. The estimated incidence of CMDs is 1 in 21,500 live births worldwide. Despite the severity of these disorders, there are currently no approved effective therapies. Dystroglycanopathy and merosin-deficient CMD type 1A (MDC1A) are two of the most common forms of CMDs [Sframeli et al., Neuromuscul Disord., 27(9):793-803(2017)].
[0006] Dystroglycanopathies are caused by mutations in any of over 18 genes required for glycosylation of α-dystroglycan. Proper glycosylation allows α-dystroglycan to bind to elements of the extracellular matrix (ECM). α-dystroglycan is then anchored to the sarcolemma by binding to β-dystroglycan, a transmembrane protein. The number of susceptibility genes precludes the development of a single gene replacement therapy for dystroglycanopathies. Examples of dystroglycanopathies include: Walker-Warburg syndrome (WWS) involves gene mutations in B3GLNT2, B4GAT1, DAG1, FKRP, FKTN, GMPPB, ISPD, or LARGE. Myo-ophthalmopathy (MEB) involves gene mutations in B3GLNT2, B4GAT1, DAG1, FKRP, FKTN, GMPPB, ISPD, or LARGE. Fukuyama-type CMD involves mutations in the FKTN gene. The group of congenital muscular dystrophies with cognitive impairment is due to mutations in FKRP, LARGE, POMT1, POMT2, or POMGNT1. The group of CMDs without cognitive impairment is the result of genetic mutations in FKRP or FKTN. The limb-girdle muscular dystrophies LGMD2I, 2K, 2M, 2N, and 2O are associated with glycosylation abnormalities with genetic mutations in FKRP, FKTN, POMGNT1, POMT1, or POMT2. The limb-girdle muscular dystrophies LGMD2T and 2U are the result of genetic mutations in GMPPB and ISPD, respectively. Other mutated genes in dystroglycanopathies include DOLK, DPM1, DPM2, DPM3, GTDC2 / AG061, TMEM5, and SK196.
[0007] MDC1A is caused by mutations in the LAMA2 gene, which encodes laminin-α2, a key ECM protein that binds glycosylated α-dystroglycan in the sarcolemma. The complete LAMA2 gene is over 9,000 base pairs in length.
[0008] A study by Reinhard and colleagues [Reinhard et al., Sci Transl Med., 9(396), (2017)] showed that germline expression of a fusion domain from laminin-α4 and miniagrin incompletely ameliorated disease symptoms in a dyW / dyW mouse model of MDC1A.
[0009] Adeno-associated virus (AAV) is a replication-deficient parvovirus whose single-stranded DNA genome is approximately 4.7 kb long, including two 145-nucleotide inverted terminal repeats (ITRs). There are multiple serotypes of AAV. The nucleotide sequences of the genomes of the AAV serotypes are known. For example, the complete genome of AAV-1 is provided in GenBank Accession No. NC_002077, the complete genome of AAV-2 is provided in GenBank Accession No. NC_001401 and in Srivastava et al., J. Virol., 45:555-564 (1983), the complete genome of AAV-3 is provided in GenBank Accession No. NC_1829, the complete genome of AAV-4 is provided in GenBank Accession No. NC_001829, the AAV-5 genome is provided in GenBank Accession No. AF085716, the complete genome of AAV-6 is provided in GenBank Accession No. NC_001862, at least portions of the AAV-7 and AAV-8 genomes are provided in GenBank Accession Nos. AX753246 and AX753249, respectively, and the AAV-9 genome is provided in Gao et al. al., J. Virol., 78:6381-6388 (2004), the AAV-10 genome is provided in Mol. Ther., 13(1):67-76 (2006), the AAV-11 genome is provided in Virology, 330(2):375-383 (2004), a portion of the AAV-12 genome is provided in GenBank Accession No. DQ813647, and a portion of the AAV-13 genome is provided in GenBank Accession No. EU285562. The sequence of the AAVrh.74 genome is provided in U.S. Patent No. 9,434,928, which is incorporated herein by reference. Cis acting sequences that direct viral DNA replication (rep), encapsidation / packaging, and host cell chromosomal integration are contained within the AAV ITR. Three AAV promoters (designated p5, p19, and p40 for their relative map positions) drive expression of two AAV internal open reading frames encoding the rep and cap genes.Two rep promoters (p5 and p19), coupled with differential splicing of a single AAV intron (at nucleotides 2107 and 2227), result in the generation of four rep proteins (rep78, rep68, rep52, and rep40) from the rep gene. The Rep proteins have multiple enzymatic properties that are ultimately involved in the replication of the viral genome. The cap gene is expressed from the p40 promoter and encodes the three capsid proteins VP1, VP2, and VP3. Alternative splicing and non-consensus translation initiation sites are responsible for the production of the three related capsid proteins. A single consensus polyadenylation site is located at map position 95 of the AAV genome. The life cycle and genetics of AAV are reviewed in Muzyczka, Current Topics in. Reviewed in Microbiology and Immunology, 158:97-129 (1992).
[0010] AAV has unique features that make it attractive as a vector for delivering foreign DNA to cells, for example in gene therapy. AAV infection of cells in culture is non-cytopathic, and natural infection of humans and other animals is silent and asymptomatic. Moreover, AAV can infect many mammalian cells, allowing the possibility of targeting many different tissues in vivo. Furthermore, AAV can transduce slowly dividing and non-dividing cells and persist essentially for the life of those cells as transcriptionally active nuclear episomes (extrachromosomal elements). The AAV proviral genome is inserted as cloned DNA within a plasmid making the construction of recombinant genomes feasible. Furthermore, signals directing AAV replication and genome encapsidation are contained within the ITRs of the AAV genome, so that part or all of the internal approximately 4.3 kb genome (encoding replication and structural capsid proteins, rep-cap) may be replaced with foreign DNA. To generate AAV vectors, the rep and cap proteins can be provided in trans. Another important feature of AAV is that it is an extremely stable and robust virus. It easily survives the conditions used to inactivate adenovirus (56°C-65°C for several hours), making cryopreservation of AAV less important. AAV can be lyophilized. Finally, AAV-infected cells are not resistant to superinfection. There remains a need in the art for treatments for CMDs, such as dystroglycanopathy and MDC1A. [Prior art documents] [Non-patent literature]
[0011] [Non-Patent Document 1] Sframeli et al., Neuromuscul Disord.,27(9):793-803(2017) [Non-Patent Document 2] Reinhard et al.,Sci Transl Med.,9(396),(2017) [Non-Patent Document 3] Srivastava et al., J. Virol., 45:555-564 (1983) Summary of the Invention [Means for solving the problem]
[0012] Methods and products are provided herein for the treatment of CMDs, such as dystroglycanopathy and laminin-deficient muscular dystrophy, including therapeutic proteins and rAAVs encoding the disclosed therapeutic proteins.
[0013] a) a first domain comprising the heparin-binding domain of heparin-binding epidermal growth factor-like growth factor (HBEGF) and a second domain comprising the G1-G5 domain of the human laminin alpha 2 (LAMA2) gene; b) a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising the G1-G5 domain of the human LAMA2 gene; c) a first domain comprising the heparin-binding domain of HBEGF and a second domain comprising the G3-G5 domain of the human LAMA2 gene; d) a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising the G3-G5 domain of the human LAMA2 gene; e) a first domain comprising the heparin-binding domain of HBEGF and a second domain comprising DAG1 alpha; or f) A polynucleotide is provided that encodes a protein comprising a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising DAG1 alpha.
[0014] In one embodiment, the provided polynucleotide encodes a protein, wherein a first domain of the protein is encoded by the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:14, and a second domain of the protein is encoded by the nucleotide sequence of SEQ ID NO:15, SEQ ID NO:16, or SEQ ID NO:17.
[0015] For example, the polynucleotide provided comprises the nucleotide sequence of SEQ ID NO:13 and SEQ ID NO:15, or comprises the nucleotide sequence of SEQ ID NO:13 and SEQ ID NO:16, or comprises the nucleotide sequence of SEQ ID NO:14 and SEQ ID NO:15, or comprises the nucleotide sequence of SEQ ID NO:14 and SEQ ID NO:16, or comprises the nucleotide sequence of SEQ ID NO:13 and SEQ ID NO:17, or comprises the nucleotide sequence of SEQ ID NO:14 and SEQ ID NO:17.
[0016] In one embodiment, the polynucleotide provided comprises one of the following: i) the nucleotide sequence depicted in FIG. 3; ii) the nucleotide sequence comprising nucleotides 14 to 3235 depicted in FIG. 3; iii) the nucleotide sequence of SEQ ID NO:1; or iv) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:19.
[0017] In another embodiment, the polynucleotide provided comprises one of the following: i) the nucleotide sequence depicted in FIG. 4; ii) the nucleotide sequence comprising nucleotides 14 to 3361 depicted in FIG. 4; iii) the nucleotide sequence of SEQ ID NO:3; or iv) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:20.
[0018] In further embodiments, the polynucleotide provided comprises one of the following: i) the nucleotide sequence depicted in FIG. 5; ii) the nucleotide sequence comprising nucleotides 14 to 1930 depicted in FIG. 5; iii) the nucleotide sequence of SEQ ID NO:5; or iv) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:21.
[0019] In another embodiment, the polynucleotide provided comprises one of the following: i) the nucleotide sequence depicted in FIG. 6; ii) the nucleotide sequence comprising nucleotides 14 to 2056 depicted in FIG. 6; iii) the nucleotide sequence of SEQ ID NO:7; or iv) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:22.
[0020] In one embodiment, the polynucleotide provided comprises one of the following: i) the nucleotide sequence depicted in FIG. 7; ii) the nucleotide sequence comprising nucleotides 14 to 1360 depicted in FIG. 7; iii) the nucleotide sequence of SEQ ID NO:9; or iv) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:23.
[0021] In another embodiment, the polynucleotide provided comprises one of the following: i) the nucleotide sequence depicted in FIG. 8; ii) the nucleotide sequence comprising nucleotides 14 to 1486 depicted in FIG. 8; iii) the nucleotide sequence of SEQ ID NO:11; or iv) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:24.
[0022] Also provided are therapeutic proteins encoded by any of the provided polynucleotides. For example, the provided proteins comprise the amino acid sequence of SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24.
[0023] In addition, the present disclosure provides a recombinant host cell comprising any of the polynucleotides described herein.In an exemplary embodiment, the host cell, the polynucleotide is operably linked to a transcriptional regulator, and these host cells express any of the polynucleotides disclosed herein.For example, the host cell is a Chinese hamster ovary (CHO) cell or a human HEK293 cell.
[0024] Further provided is a recombinant adeno-associated virus (rAAV), the genome of the rAAV comprises any of the polynucleotides described herein.For example, a rAAV is provided, the genome of the rAAV comprises the polynucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO:11.In an exemplary embodiment, the rAAV genome further comprises a muscle-specific transcription regulator, such as a CMV promoter (SEQ ID NO:18), MCK, NHCK, LAMA2, or tMCK.Any of the rAAVs described herein comprise AAV9, AAV10, AAVrh74, AAV8, or AAV6 capsid.
[0025] Also provided is an rAAV, the genome of which comprises nucleotides 3590-8215 of SEQ ID NO:2, nucleotides 3590-8341 of SEQ ID NO:4, nucleotides 3609-6929 of SEQ ID NO:6, nucleotides 3590-7036 of SEQ ID NO:8, nucleotides 3590-6340 of SEQ ID NO:10, nucleotides 3590-6049 of SEQ ID NO:12, the nucleotide sequence shown in Figure 13, or the nucleotide sequence shown in Figure 14.
[0026] Also provided are rAAV particles comprising any of the rAAVs described herein. The disclosure also provides compositions comprising any of the polynucleotides disclosed herein, any of the rAAVs disclosed herein, any of the rAAV particles disclosed herein, or any of the proteins disclosed herein.
[0027] A method for treating laminin-deficient muscular dystrophy is provided, comprising administering to a patient in need of treatment an rAAV, the genome of which comprises: a) a first domain comprising the heparin-binding domain of HBEGF, and a second domain comprising the G1-G5 domain of the human LAMA2 gene; b) a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising the G1-G5 domain of the human LAMA2 gene; c) a first domain comprising the heparin-binding domain of HBEGF and a second domain comprising the G3-G5 domain of the human LAMA2 gene; or d) It comprises a polynucleotide encoding a protein comprising a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising the G3-G5 domain of the human LAMA2 gene.
[0028] For example, a method of treating laminin-deficient muscular dystrophy includes administering to a patient in need of treatment any of the following: any of the polynucleotides disclosed herein that encode a protein comprising LAMA2(G1-G5) or LAMA2(G3-G5) as the second domain, any of the rAAV or rAAV particles disclosed herein that include a polynucleotide encoding a protein comprising LAMA2(G1-G5) or LAMA2(G3-G5) as the second domain.
[0029] Further provided is a method for treating laminin-deficient muscular dystrophy, comprising administering to a patient in need of treatment: a) a first domain comprising the heparin-binding domain of HBEGF, and a second domain comprising the G1-G5 domain of the human LAMA2 gene; b) a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising the G1-G5 domain of the human LAMA2 gene; c) a first domain comprising the heparin-binding domain of HBEGF and a second domain comprising the G3-G5 domain of the human LAMA2 gene; or d) administering a protein comprising a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising the G3-G5 domain of the human LAMA2 gene.
[0030] For example, a method for treating laminin-deficient muscular dystrophy includes administering to a patient in need of treatment a protein, wherein the protein comprises the amino acid sequence of SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22.
[0031] Also provided is a composition for treating laminin-deficient muscular dystrophy comprising an rAAV, the genome of which comprises: a) a first domain comprising the heparin-binding domain of HBEGF, and a second domain comprising the G1-G5 domain of the human LAMA2 gene; b) a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising the G1-G5 domain of the human LAMA2 gene; c) a first domain comprising the heparin-binding domain of HBEGF and a second domain comprising the G3-G5 domain of the human LAMA2 gene; or d) It comprises a polynucleotide encoding a protein comprising a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising the G3-G5 domain of the human LAMA2 gene.
[0032] For example, a composition for treating laminin-deficient muscular dystrophy includes any of the following: any of the polynucleotides disclosed herein that encode a protein comprising LAMA2(G1-G5) or LAMA2(G3-G5) as the second domain, any of the rAAV or rAAV particles disclosed herein that include a polynucleotide encoding a protein comprising LAMA2(G1-G5) or LAMA2(G3-G5) as the second domain.
[0033] Further provided is a composition for treating laminin-deficient muscular dystrophy comprising a protein, the protein comprising: a) a first domain comprising the heparin-binding domain of HBEGF, and a second domain comprising the G1-G5 domain of the human LAMA2 gene; b) a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising the G1-G5 domain of the human LAMA2 gene; c) a first domain comprising the heparin-binding domain of HBEGF and a second domain comprising the G3-G5 domain of the human LAMA2 gene; or d) A first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising the G3-G5 domain of the human LAMA2 gene.
[0034] For example, a composition for treating laminin-deficient muscular dystrophy includes a protein, the protein comprising the amino acid sequence of SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22.
[0035] The present disclosure also provides a use of an rAAV for the preparation of a medicament for treating a laminin-deficient muscular dystrophy in a patient in need of such treatment, the genome of the rAAV comprising: a) a first domain comprising the heparin-binding domain of HBEGF, and a second domain comprising the G1-G5 domain of the human LAMA2 gene; b) a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising the G1-G5 domain of the human LAMA2 gene; c) a first domain comprising the heparin-binding domain of HBEGF and a second domain comprising the G3-G5 domain of the human LAMA2 gene; or d) It comprises a polynucleotide encoding a protein comprising a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising the G3-G5 domain of the human LAMA2 gene.
[0036] For example, the disclosure also provides the use of any of the following: any of the polynucleotides disclosed herein encoding a protein comprising LAMA2(G1-G5) or LAMA2(G3-G5) as a second domain, any of the rAAV or rAAV particles disclosed herein comprising a polynucleotide encoding a protein comprising LAMA2(G1-G5) or LAMA2(G3-G5) as a second domain, for the preparation of a medicament for treating, in a patient in need of treatment, a laminin-deficient muscular dystrophy.
[0037] The disclosure further provides a use of a protein for the preparation of a medicament for treating a laminin-deficient muscular dystrophy in a patient in need thereof, the protein comprising: a) a first domain comprising the heparin-binding domain of HBEGF, and a second domain comprising the G1-G5 domain of the human LAMA2 gene; b) a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising the G1-G5 domain of the human LAMA2 gene; c) a first domain comprising the heparin-binding domain of HBEGF and a second domain comprising the G3-G5 domain of the human LAMA2 gene; or d) A first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising the G3-G5 domain of the human LAMA2 gene.
[0038] For example, the disclosure also provides the use of a protein for the preparation of a medicament for treating a laminin-deficient muscular dystrophy in a patient in need of such treatment, wherein the protein comprises the amino acid sequence of SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22.
[0039] Also provided is a method for treating dystroglycanopathy, comprising administering to a patient in need of treatment an rAAV, the genome of which comprises: a) a first domain comprising the heparin-binding domain of HBEGF, and a second domain comprising DAG1 alpha, or b) comprising a polynucleotide encoding a protein comprising a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising DAG1 alpha.
[0040] For example, a method of treating dystroglycanopathy includes administering to a patient in need of treatment any of the following: any of the polynucleotides disclosed herein that encode a protein comprising DAG1 alpha as a second domain, any of the rAAV or rAAV particles disclosed herein that include a polynucleotide encoding a protein comprising DAG1 alpha as a second domain.
[0041] Still further provided is a method for treating dystroglycanopathy, comprising administering to a patient in need of treatment: a) a first domain comprising the heparin-binding domain of HBEGF, and a second domain comprising DAG1 alpha, or b) administering a protein comprising a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising DAG1 alpha.
[0042] For example, a method for treating dystroglycanopathy comprising administering to a patient in need of treatment a protein, wherein the protein comprises the amino acid sequence of SEQ ID NO:23 or SEQ ID NO:24.
[0043] Also provided is a composition for treating dystroglycanopathy comprising an rAAV, the genome of the rAAV comprising: a) a first domain comprising the heparin-binding domain of HBEGF, and a second domain comprising DAG1 alpha, or b) comprising a polynucleotide encoding a protein comprising a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising DAG1 alpha.
[0044] For example, the disclosure provides a composition for treating dystroglycanopathy comprising any of the following: any of the polynucleotides disclosed herein that encode a protein that comprises DAG1 alpha as a second domain, or any of the rAAV or rAAV particles disclosed herein that comprise a polynucleotide that encodes a protein that comprises DAG1 alpha as a second domain.
[0045] Still further provided is a composition for treating dystroglycanopathy comprising a protein, the protein comprising: a) a first domain comprising the heparin-binding domain of HBEGF, and a second domain comprising DAG1 alpha, or b) comprising a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising DAG1 alpha.
[0046] For example, a composition for treating dystroglycanopathy includes a protein, the protein comprising the amino acid sequence of SEQ ID NO:23 or SEQ ID NO:24.
[0047] Also provided is the use of an rAAV for the preparation of a medicament for treating a dystroglycanopathy in a patient in need of such treatment, the genome of the rAAV comprising: a) a first domain comprising the heparin-binding domain of HBEGF, and a second domain comprising DAG1 alpha, or b) comprising a polynucleotide encoding a protein comprising a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising DAG1 alpha.
[0048] For example, the disclosure provides any of the following: the use of any of the polynucleotides disclosed herein encoding a protein comprising DAG1 alpha as a second domain, or any of the rAAV or rAAV particles disclosed herein comprising a polynucleotide encoding a protein comprising DAG1 alpha as a second domain, for the preparation of a medicament for treating, in a patient in need of treatment for a dystroglycanopathy.
[0049] There is still further provided a use of a protein for the preparation of a medicament for treating a dystroglycanopathy in a patient in need thereof, the protein comprising: a) a first domain comprising the heparin-binding domain of HBEGF, and a second domain comprising DAG1 alpha, or b) comprising a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising DAG1 alpha.
[0050] For example, the disclosure provides the use of a protein for the preparation of a medicament for treating dystroglycanopathy in a patient in need of such treatment, wherein the protein comprises the amino acid sequence of SEQ ID NO:23 or SEQ ID NO:24.
[0051] In the provided methods, uses, or compositions for treating a laminin deficient muscular dystrophy, the laminin deficient muscular dystrophy may be, for example, MDC1A.
[0052] In any of the methods, uses or compositions for treating a dystroglycanopathy, the dystroglycanopathy is, for example, Walker-Warburg syndrome, myo-oculo-encephalopathy, Fukuyama congenital muscular dystrophy, MDC1C, MDC1D, LGMD2I, LGMD2K, LGMD2M, LGMD2N, LGMD2O, LGMD2P, LGMD2T, or LGMD2U.
[0053] Examples of proteins that are provided are shown in Table 1. [Table 1]
[0054] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings and color photographs will be provided by the Office upon request and payment of the necessary fee. [Brief description of the drawings]
[0055] [Figure 1-1] [Figure 1A] Dystrophin-associated glycoprotein (DAG) complex. [Figure 1B] Not only is α-dystroglycan abnormally glycosylated in dystroglycanopathies (losing its normal laminin-binding function), but α-dystroglycan protein is reduced in affected muscles. [Figure 1C] The therapeutic proteins described herein link α-dystroglycan to muscle membrane by binding to β-dystroglycan, which is present in normal amounts, and allow it to link to the ECM in the absence of its appropriate ECM-binding glycan through binding of HBEGF to the heparin sulfate proteoglycans of the ECM. This reconstitutes the lost link of α-dystroglycan to the ECM and muscle membrane. The use of the methods described herein to provide these therapeutic proteins is applicable to the treatment of all 18 or more genetic types of dystroglycanopathies, making the methods a powerful alternative to gene replacement strategies, where each dystroglycanopathies requires the development of a different gene therapy. [Figure 1-2] Same as above. [Figure 2-1][Figure 2A] MDC1A is caused by a loss-of-function mutation in the LAMA2 gene, which encodes laminin α2, an extracellular matrix (ECM) protein that surrounds each muscle cell in the body. LAMA2 is required for muscle cell adhesion to the ECM and muscle membrane stability. [Figure 2B] The therapeutic proteins described herein show that the LAMA2 G1-G5 domain can function similarly to native laminin α2, as they can anchor the LAMA2 G1-G5 domain to the ECM where it normally resides. Thus, the use of the methods described herein to provide these therapeutic proteins is adapted to MDC1A. [Figure 2-2] Same as above. [Figure 3-1] 1 shows the polynucleotide sequence encoding the therapeutic protein HB-EGF (ending in the heparin binding domain)-LAMA2 G1-G5. The therapeutic protein comprises nucleotides 14 to 3235, which are encoded by the nucleotides of the invention and also correspond to SEQ ID NO:1. [Figure 3-2] Same as above. [Figure 3-3] Same as above. [Diagram 3-4] Same as above. [Figure 4-1] 1 shows the polynucleotide sequence encoding the therapeutic protein HB-EGF (fully soluble)-LAMA2 G1-G5. The therapeutic protein is encoded by the nucleotides of the present invention and includes nucleotides 14 to 3361, which also correspond to SEQ ID NO:3. [Figure 4-2] Same as above. [Figure 4-3] Same as above. [Figure 4-4] Same as above. [Figure 4-5] Same as above. [Figure 4-6] Same as above. [Diagram 4-7] Same as above. [Figure 5-1]1 shows the polynucleotide sequence encoding the therapeutic protein HB-EGF (ending in the heparin binding domain)-LAMA2 G3-G5. The therapeutic protein comprises nucleotides 14-1930, which are encoded by the nucleotides of the invention and also correspond to SEQ ID NO:5. [Figure 5-2] Same as above. [Figure 5-3] Same as above. [Figure 6-1] 1 shows the polynucleotide sequence encoding the therapeutic protein HB-EGF (fully soluble)-LAMA2 G3-G5. The therapeutic protein is encoded by the nucleotides of the present invention and includes nucleotides 14 to 2056, which also correspond to SEQ ID NO: 7. [Figure 6-2] Same as above. [Figure 7-1] 1 shows a polynucleotide sequence encoding the therapeutic protein HB-EGF (ending in the heparin binding domain)-DAG1 (the native processed alpha-DG gene). The therapeutic protein is encoded by the nucleotides of the invention and includes nucleotides 14 to 1360, which also correspond to SEQ ID NO:9. [Figure 7-2] Same as above. [Figure 8-1] 1 shows a polynucleotide sequence encoding the therapeutic protein HB-EGF (intact soluble)-DAG1 (native processed alpha-DG gene). The therapeutic protein is encoded by the nucleotides of the present invention and includes nucleotides 14 to 1486, which also correspond to SEQ ID NO: 11. [Figure 8-2] Same as above. [Figure 8-3] Same as above. [Figure 8-4] Same as above. [Figure 9-1] 1 shows expression of a therapeutic protein described herein by a recombinant mammalian host cell. [Figure 9-2] Same as above. [Figure 10] We show that sHB-EGF can be secreted from muscle and adheres to the extracellular matrix. [Figure 11]sHB-EGF induces expression of a therapeutic surrogate muscular dystrophy gene. Full-length HBEGF does not induce therapeutic gene expression. [Figure 12] We show that sHB-EGF can induce the Akt tyrosine kinase cascade in skeletal muscle and stimulate muscle growth and regeneration. [Figure 13-1] An exemplary rAAV genome encoding the therapeutic proteins HB-EGF (fully soluble)-LAMA2 G1-G5 is shown. [Figure 13-2] Same as above. [Figure 13-3] Same as above. [Figure 13-4] Same as above. [Figure 14-1] An exemplary rAAV genome encoding the therapeutic proteins HB-EGF (intact, soluble)-DAG1 (native, processed alpha-DG gene). [Figure 14-2] Same as above. [Figure 14-3] Same as above. [Figure 15] Immunohistochemical staining of HB-EGF and LG5 (represented as 4H8-2 in the figure) following intramuscular injection of rAAV9.CMV vectors containing HBEGF, HBEGF.LAMA2(G1-G5), HBEGF.LAMA2(G3-G5), HB.LAMA2(G1-G5), HB.LAMA2(G3-G5), or LAMA2(G1-G5) in wild type mice. Sham-injected mice (buffer only) are shown as negative controls. 4H8-2 is an anti-laminin antibody that shows muscle cells in sections. [Figure 16] Immunohistochemical staining of HB-EGF and laminin globular domain (LG5) in muscles injected IM with rAAV9.HBEGF-LAMA2(G1-G5), HB-LAMA2(G1-G5), or LAMA2(G1-G5) is provided. The bottom panel below shows staining with secondary antibody only. [Figure 17]1 is a graph showing that rAAV9.CMV.HB.LAMA(G1-G5) prevented muscle weakness in dy / dy mice. Mice were injected IV with 1×1012 vg of rAAV9.CMV vectors containing HBEGF.LAMA2(G1-G5), HB.LAMA2(G1-G5), or HB.LAMA2(G3-G5). Mice were compared to sham-injected dy / dy disease controls and wild-type normal controls at 2 and 3 months post-injection. Mixed (50:50) female:male gender was used in all groups. Errors are SEM for n=12 (wild-type and sham dy / dy), 6 (sHB-EGF.LAMA2G1-G5 and HB.LAMA2G1-G5) or 5 (HB.LAMA2G3-G5) animals per group, averaging 5 measurements per data point. *p<0.05, **p<0.01, ***p<0.001 [Figure 18] Immunohistochemical staining for HB-EGF and LG5 is provided to show expression of HB.LAMA2(G1-G5) in 4-month-old dy / dy muscles (triceps) after IV injection at P1. Muscle sections from triceps of 4-month-old wild-type and dy / dy mice either sham-injected or injected with 1x1012 vg of rAAV9.CMV.HB-LAMA2(G1-G5) were stained with antibodies specific for HBEGF (green) to recognize the transgenic protein, and collagen IV (Col(IV), red) to recognize all muscle cells. DAPI has been added in blue to stain nuclei. Merged tricolor images are shown. [Figure 19-1] The plasmid sequence of pAAV.CMV.HB.LAMA1(G1-G5) is provided (SEQ ID NO:2), with the rAAV genome corresponding to nucleotides 3590 to 8215. [Figure 19-2] Same as above. [Figure 19-3] Same as above. [Figure 19-4] Same as above. [Figure 20-1] The plasmid sequence of pAAV.CMV.HBEGF LAMA2(G1-G5) is provided (SEQ ID NO:4), with the rAAV genome corresponding to nucleotides 3590 to 8341. [Figure 20-2] Same as above. [Figure 20-3] Same as above. [Figure 20-4] Same as above. [Figure 21-1] The plasmid sequence of pAAV.CMV.HB LAMA2(G3-G5) is provided (SEQ ID NO:6), the rAAV genome corresponds to nucleotides 36909 to 6929. [Figure 21-2] Same as above. [Figure 21-3] Same as above. [Figure 21-4] Same as above. [Figure 22-1] The plasmid sequence of pAAV.CMV.HBEGF.LAMA2(G3-G5) is provided (SEQ ID NO:8), with the rAAV genome corresponding to nucleotides 3590 to 7036. [Figure 22-2] Same as above. [Figure 22-3] Same as above. [Figure 23-1] The plasmid sequence of pAAV.CMV.HB.DAG1(alpha) is provided (SEQ ID NO: 10), where the rAAV genome corresponds to nucleotides 3590 to 6340. [Figure 23-2] Same as above. [Figure 23-3] Same as above. [Figure 24-1] The plasmid sequence of pAAV.CMV.HB.DAG1(alpha) is provided (SEQ ID NO: 12), the rAAV genome corresponds to nucleotides 3590 to 6049. [Figure 24-2] Same as above. [Figure 24-3] Same as above. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0056] Provided herein are methods and products for the treatment of dystroglycanopathies (including, but not limited to, Walker-Warburg syndrome, myo-oculo-encephalopathy, Fukuyama congenital muscular dystrophy, MDC1C, MDC1D, LGMD2I, LGMD2K, LGMD2M, LGMD2N, LGMD2O, LGMD2P, LGMD2T, and LGMD2U) and laminin-deficient muscular dystrophies (including, but not limited to, MDC1A) that utilize the lysine-rich heparin-binding domain of HBEGF. Heparin sulfate proteoglycans are abundant in the extracellular matrix (ECM), and as shown herein, overexpression of HBEGF in muscle leads to localization of HBEGF in the muscle ECM. In the methods described herein, the membrane anchoring defects in dystroglycanopathies and laminin-deficient muscular dystrophies are treated using the heparin-binding domain of HBEGF as a "linker" domain for a therapeutic protein.
[0057] Here, the term "HBEGF" refers to the entire HBEGF sequence up to the bioactive EGF domain, but lacks the transmembrane domain, which allows HBEGF secretion (Figure 4). The HBEGF fragment contains four domains from the HBEGF gene: a signal peptide that allows entry into the secretory pathway, a pre-propeptide that allows protein folding and stabilization, a heparin binding domain that allows increased interaction with the extracellular matrix, and a bioactive EGF domain that allows HBEGF signaling. In the proteins disclosed herein, the coding sequences for these domains are then linked to laminin alpha 2 or dystroglycan coding sequences. A second "HB" fragment is also used (Figure 3). The HB fragment contains only three of the four domains found in HBEGF: the signal peptide, the pre-propeptide, and the heparin binding domain (hence, HB lacks the bioactive EGF domain). When linked to laminin alpha 2 or dystroglycan protein fragments, the HB domain can increase association with the ECM, but not increase EGF or HBEGF signaling.
[0058] The HBEGF or HB linker domain acts to target the protein to the extracellular matrix of a cell, anchoring the protein to the extracellular domain of a cell, such as a muscle cell. A polynucleotide encoding a therapeutic protein is delivered to a patient (e.g., by a recombinant AAV encoding a therapeutic protein), or a therapeutic protein is delivered to a patient.
[0059] For example, for all dystroglycanopathies, the coding sequence for the HBEGF heparin-binding domain is fused to the coding sequence for α-dystroglycan to generate a polynucleotide encoding the therapeutic protein HBEGF-DAG1(α). In addition to hypoglycosylation of α-dystroglycan, α-dystroglycan protein levels are reduced in dystroglycanopathies. In the methods described herein, the HBEGF domain of HBEGF-DAG1(α) binds to ECM heparin sulfate proteoglycans, while the α-dystroglycan domain binds to β-dystroglycan, linking the sarcolemma to the ECM despite hypoglycosylation in dystroglycanopathies. Four examples of such HBEGF-DAG1(α) therapeutic proteins are: HB-EGF (ending in the heparin-binding domain)-LAMA2 G1-G5 (encoded by the polynucleotide of FIG. 3 ); HB-EGF (fully soluble)-LAMA2 G1-G5 (encoded by the polynucleotide of FIG. 4 ); HB-EGF (ending in the heparin-binding domain)-LAMA2 G3-G5 (encoded by the polynucleotide of FIG. 5 ), and HB-EGF (fully soluble)-LAMA2 G3-G5 (encoded by the polynucleotide of Figure 6).
[0060] The term "fully soluble" herein indicates that the therapeutic protein contains the HBEGF heparin-binding domain and the EGF-like domain, but does not contain the transmembrane portion of HBEGF. The combination of the HBEGF heparin-binding domain and the EGF-like domain of HBEGF corresponds to the soluble isoform of the truncated activity of HBEGF. This term is referred to herein as "HBEGF".
[0061] The term "terminating in a heparin-binding domain" herein indicates that the therapeutic protein contains only the HBEGF heparin-binding domain, and does not contain the EGF-like domain or transmembrane portion of HBEGF. This term is abbreviated herein as "HB."
[0062] For example, for laminin-deficient muscular dystrophies such as MDC1A, the coding sequence for the HBEGF heparin-binding domain is fused to the coding sequence for the globular (G) domains 1-5 of laminin-α2 to generate a polynucleotide encoding the therapeutic protein HBEGF-LAMA2(G1-5). The laminin-α2 G domain binds to α-dystroglycan glycosylated at the sarcolemma and also to integrins, and is encoded by a portion of the LAMA2 gene. In the methods described herein, the HBEGF domain of HBEGF-LAMA2(G1-5) binds to ECM heparin sulfate proteoglycans and the G domain binds to α-dystroglycan, linking the sarcolemma to the ECM, despite the absence of full-length laminin-α2 in MDC1A. Two examples of such HBEGF-LAMA2(G1-5) therapeutic proteins are: HB-EGF (ending in the heparin binding domain)-DAG1 (the native processed alpha-DG gene) (encoded by the polynucleotide of FIG. 7); and HB-EGF (intact soluble)-DAG1 (native processed alpha-DG gene) (encoded by the polynucleotide of FIG. 8).
[0063] Additionally, both dystroglycanopathies and laminin-deficient muscular dystrophies (such as MDC1A) are associated with reduced muscle regeneration, and in embodiments of the methods described herein in which the therapeutic protein comprises the HBEGF heparin-binding domain and the HBEGF EGF-like domain, patients also benefit from the trophic signaling of the HBEGF EGF-like domain of the therapeutic protein, resulting in altered expression of genes including Pax7, MyoD, myogenin, and Myh3, leading to increased myogenesis and muscle regeneration.
[0064] Thus, polynucleotides encoding therapeutic proteins are provided. Embodiments include polynucleotides comprising a polynucleotide sequence as shown in Figure 3, 4, 5, 6, 7, or 8. Other embodiments include polynucleotides that encode the same amino acid sequence as the polynucleotide sequence as shown in Figure 3, 4, 5, 6, 7, or 8. Still other embodiments include polynucleotides that comprise a polynucleotide consisting of the polynucleotide sequence as shown in Figure 3, 4, 5, 6, 7, or 8.
[0065] In one embodiment, the polynucleotide provided comprises one of the following: i) the nucleotide sequence depicted in FIG. 3; ii) the nucleotide sequence comprising nucleotides 14 to 3235 depicted in FIG. 3; iii) the nucleotide sequence of SEQ ID NO:1; or iv) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:19.
[0066] In another embodiment, the polynucleotide provided comprises one of the following: i) the nucleotide sequence depicted in FIG. 4; ii) the nucleotide sequence comprising nucleotides 14 to 3361 depicted in FIG. 4; iii) the nucleotide sequence of SEQ ID NO:3; or iv) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:20.
[0067] In further embodiments, the polynucleotide provided comprises one of the following: i) the nucleotide sequence depicted in FIG. 5; ii) the nucleotide sequence comprising nucleotides 14 to 1930 depicted in FIG. 5; iii) the nucleotide sequence of SEQ ID NO:5; or iv) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:21.
[0068] In another embodiment, the polynucleotide provided comprises one of the following: i) the nucleotide sequence depicted in FIG. 6; ii) the nucleotide sequence comprising nucleotides 14 to 2056 depicted in FIG. 6; iii) the nucleotide sequence of SEQ ID NO:7; or iv) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:22.
[0069] In one embodiment, the polynucleotide provided comprises one of the following: i) the nucleotide sequence depicted in FIG. 7; ii) the nucleotide sequence comprising nucleotides 14 to 1360 depicted in FIG. 7; iii) the nucleotide sequence of SEQ ID NO:9; or iv) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:23.
[0070] In another embodiment, the polynucleotide provided comprises one of the following: i) the nucleotide sequence depicted in FIG. 8; ii) the nucleotide sequence comprising nucleotides 14 to 1486 depicted in FIG. 8; iii) the nucleotide sequence of SEQ ID NO:11; or iv) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:24.
[0071] Other polynucleotides provided include, but are not limited to, polynucleotides encoding amino acid variants of a Therapeutic polypeptide that retain the binding activity of the Therapeutic protein, which have a nucleotide sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleotide sequence encoding a protein shown in Figures 3, 4, 5, 6, 7, or 8 or to the nucleotide sequence of any of the provided polynucleotides.
[0072] Also provided herein are polynucleotides encoding amino acid variants of therapeutic polypeptides that retain the binding activity of the therapeutic protein, which hybridize under stringent conditions to the nucleotide sequences encoding the proteins shown in Figures 3, 4, 5, 6, 7, or 8 or their complements, or to the nucleotide sequences of any of the polynucleotides provided. The term "stringent" is used to refer to conditions that are generally understood in the art as stringent. Hybridization stringency is determined primarily by temperature, ionic strength, and the concentration of denaturing agents, such as formamide. Examples of stringent conditions for hybridization and washing are 0.015 M sodium chloride, 0.0015 M sodium citrate at 65-68°C or 0.015 M sodium chloride, 0.0015 M sodium citrate, and 50% formamide at 42°C. Sambrook et al., Molecular Cloning: A Laboratory Manual, 2 nd Ed., Cold Spring Harbor Laboratory, (Cold Spring Harbor, NY 1989).
[0073] "Retains binding activity" is intended to mean herein that an amino acid variant of a Therapeutic protein encoded by a polynucleotide competes for binding to heparin sulfate proteoglycan and β-dystroglycan with a Therapeutic protein encoded by a nucleotide sequence shown in Figure 3, 4, 5, or 6, or for binding to heparin sulfate proteoglycan and α-dystroglycan with a Therapeutic protein encoded by a nucleotide sequence shown in Figure 7 or 8, or for binding to heparin sulfate proteoglycan and α-dystroglycan with a Therapeutic protein comprising the amino acid sequence of SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24.
[0074] Also provided is a recombinant expression vector comprising one or more of the polynucleotides described herein. Also provided is a recombinant AAV genome comprising the polynucleotides described herein.
[0075] In the expression vector or recombinant AAV genome described herein, the polynucleotide encoding the therapeutic protein is operably linked to a transcriptional regulator (including but not limited to a promoter, an enhancer, and / or an intron), particularly a transcriptional regulator that is functional in the target cell of interest. For example, suitable promoters for use in mammalian host cells are well known and include, but are not limited to, those obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus (such as adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, retrovirus, hepatitis B virus, and simian virus 40 (SV40). Other suitable mammalian promoters include heterologous mammalian promoters, such as heat shock promoters and actin promoters.Also, for example, AAV delivery methods can be used to regulate the expression of regulators derived from the actin and myosin gene families, such as the myoD gene family [see Weintraub et al., Science, 251:761-766 (1991)], muscle cell-specific enhancer binding factor MEF-2 [Cserjesi and Olson, Mol Cell Biol, 11:4854-4862 (1991)], the human skeletal actin gene [Muscat et al., Mol Cell Biol, 7:4089-4099 (1987)], muscle creatine kinase sequence factor [see Johnson et al., Mol Cell Biol, 9:3393-3399 (1989)], and mouse creatine kinase enhancer (mCK) factor, the skeletal fast-twitch troponin C gene, the slow-twitch cardiac troponin C gene, and the slow-twitch troponin I gene: hypoxia-inducible nuclear factor [Semenza et al., Mol Cell Biol, 1999]. al., Proc Natl Acad Sci USA, 88:5680-5684 (1991)], steroid-inducible factors and promoters including glucocorticoid response elements (GREs) [Mader and White, Proc. Natl. Acad. Sci. USA, 90:5603-5607 (1993)], tMCK promoter [see Wang et al., Gene Therapy, 15:1489-1499 (2008)], hybrid alpha-myosin heavy chain enhancer- / MCK enhancer-promoter (MHCK7) promoter [Salva et al. Mol Ther, 15:320-329 (2007)], CK6 promoter [see Wang et al., supra], as well as other regulators. Thus, one example of a muscle-specific transcription regulator is the tMCK promoter. An example of a liver-specific promoter is LSP [Wang and Verma, Proc. Natl. Acad. Sci. USA, 96, 3906-3910 (1999)].As an example of another promoter, for production of a therapeutic protein in a recombinant host cell, the promoter can be a constitutive promoter, such as the cytomegalovirus (CMV) promoter. Another example is LAMA2.
[0076] For the expression of therapeutic proteins described herein, expression systems and constructs in the form of plasmids, expression vectors, transcription or expression cassettes containing at least one polynucleotide described herein, as well as host cells containing such expression systems or constructs are provided and are provided. As used herein, "vector" refers to any molecule or entity (e.g., polynucleotide, plasmid, bacteriophage, or virus) suitable for use in introducing protein coding information into a host cell. Examples of vectors include, but are not limited to, plasmids, viral vectors, non-episomal mammalian vectors, and expression vectors, such as recombinant expression vectors. Expression vectors, such as recombinant expression vectors, are useful for transforming host cells.
[0077] A host cell is provided into which an expression vector, such as a recombinant expression vector, is introduced. The host cell can be any prokaryotic cell (e.g., E. coli) or eukaryotic cell (e.g., yeast, insect, or mammalian cell (e.g., CHO cell)). The expression vector can be introduced into the prokaryotic or eukaryotic cell via conventional transformation or transfection techniques. For stable transfection of mammalian cells, a gene encoding a selectable marker (e.g., for resistance to antibiotics) is generally introduced into the host cell along with the gene of interest. Preferred selectable markers include those that confer resistance to drugs such as G418, hygromycin, and methotrexate. Cells stably transfected with the introduced polynucleotide can be identified by drug selection, among other methods. Methods for introducing heterologous polynucleotides into mammalian cells are well known in the art and include, but are not limited to, dextran-mediated transfection, calcium phosphate precipitation, polybrene-mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) into liposomes, mixing the nucleic acid with positively charged lipids, and direct microinjection of DNA into the nucleus.
[0078] The method selected will be, in part, a function of the type of host cell used. These and other suitable methods are well known to those of skill in the art and are described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 2001.
[0079] When cultured under appropriate conditions, the host cells synthesize the protein, which can then be collected from the culture medium (if the host cells secrete the protein into the medium) or directly from the host cells that produce it (if not dissolved). The selection of an appropriate host cell depends on a variety of factors, such as the desired expression level, the polypeptide modifications (such as glycosylation or phosphorylation) that are desirable or necessary for activity, and the ease of folding into a biologically active molecule. As an example, Chinese hamster ovary cells overexpressing LARGE (CHO-LARGE cells) [Yoon et al., A Method to Produce and Purify Full-Length Recombinant Alpha Dystroglycan: Analysis of N- and O-Linked Monosaccharide Composition in CHO Cells with or without LARGE Overexpression, PLoS Curr. (2013 January 2)] is contemplated for use in the production of glycosylated therapeutic proteins as described herein.
[0080] Mammalian cell lines available as hosts for expression are well known in the art and include, but are not limited to, immortalized cell lines available from the American Type Culture Collection (ATCC), including, but not limited to, Chinese hamster ovary (CHO) cells, CHO-LARGE cells, HEK293 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and other cell lines standard in the art.
[0081] The rAAV genome provided herein lacks AAV rep and cap DNA. The recombinant AAV genome provided herein comprises a polynucleotide encoding a therapeutic protein as described above, and one or more AAV ITRs flanking the polynucleotide. The AAV DNA in the rAAV genome can be from any AAV serotype from which the recombinant virus can be derived, including, but not limited to, AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, AAV-13, and AAV rh.74. Other types of rAAV mutants are also contemplated, such as rAAVs with capsid mutations. See, for example, Marsic et al., Molecular Therapy, 22(11):1900-1909 (2014). As described in the Background section above, the nucleotide sequences of the genomes of various AAV serotypes are known in the art. AAV1, AAV5, AAV6, AAV8, or AAV9 can be used to promote skeletal muscle-specific expression.
[0082] A DNA plasmid is provided that contains the rAAV genome. The DNA plasmid is introduced into a cell that is permissive for the infection of AAV with a helper virus (including, but not limited to, adenovirus, E1-deleted adenovirus, or herpesvirus) for the assembly of the rAAV genome into infectious viral particles. The technology of producing rAAV particles is standard in the art, in which the AAV genome to be packaged, rep and cap genes, and helper virus functions are provided to the cell. The production of rAAV requires the following components to be present in a single cell (referred to herein as packaging cell): the rAAV genome, the AAV rep and cap genes separated from (i.e., not present in) the rAAV genome, and the helper virus functions. The AAV ITRs and rep and cap genes can be from any AAV serotype from which the recombinant virus can be derived, and can be from an AAV serotype different from the rAAV genomic ITRs, including, but not limited to, AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, AAV-13, and AAV rh.74. The generation of pseudotyped rAAV is disclosed, for example, in WO01 / 83692, which is incorporated herein by reference in its entirety.
[0083] The method to generate packaging cells is to create a cell line that stably expresses all the components required for the production of AAV particles. For example, a plasmid (or multiple plasmids) containing a rAAV genome lacking the AAV rep and cap genes, the AAV rep and cap genes separated from the rAAV genome, and a selectable marker such as a neomycin resistance gene is integrated into the genome of the cell. The AAV genome has been introduced into a bacterial plasmid by procedures such as GC tailing (Samulski et al., 1982, Proc. Natl. Acad. S6. USA, 79:2077-2081), addition of a synthetic linker containing a restriction endonuclease cleavage site (Laughlin et al., 1983, Gene, 23:65-73), or direct blunt-end ligation (Senapathy & Carter, 1984, J. Biol. Chem., 259:4661-4666). The packaging cell line is then infected with a helper virus such as adenovirus. The advantage of this method is that the cells are selectable and are suitable for large-scale production of rAAV. Other examples of suitable methods use adenovirus or baculovirus rather than plasmids to introduce the rAAV genome and / or the rep and cap genes into the packaging cells.
[0084] General principles of rAAV production are reviewed in, e.g., Carter, Current Opinions in Biotechnology, 1533-1539 (1992); and Muzyczka, Curr. Topics in Microbial. And Immunol., 158:97-129 (1992). Various approaches are described by Ratschin et al., Mol. Cell. Biol., 4:2072 (1984), Hermonat et al., Proc. Natl. Acad. Sci. USA, 81:6466 (1984), Tratschin et al., Mo1. Cell. al., J.Virol.,62:1963(1988), ebkowski et al.,Mol.Cell.Biol.,7:349(1988), Samulski et al. al., J. Virol., 63:3822-3828 (1989); U.S. Pat. No. 5,173,414, WO95 / 13365 and corresponding U.S. Pat. No. 5,658.776, WO95 / 13392, WO96 / 17947, PCT / US98 / 18600, WO97 / 09441 (PCT / US96 / 14423), WO97 / 08298 (PCT / US96 / 13872), WO97 / 21825 (PCT / US96 / 20777), WO97 / 06243 (PCT / FR96 / 01064), WO 99 / 11764, Perrin et al., Vaccine, 13:1244-1250 (1995), Paul et al. al., Human Gene Therapy, 4:609-615 (1993), Clark et al., Gene Therapy 3:1124-1132 (1996), U.S. Patent No. 5,786,211, U.S. Patent No. 5,871,982, U.S. Patent No. 6,258,595, and McCarty, Mol. Ther., 16(10):1648-1656 (2008). The foregoing documents are incorporated herein by reference in their entireties, with particular emphasis on the portions of the documents relating to rAAV production.
[0085] Therefore, the present invention provides a packaging cell that produces infectious rAAV.In one embodiment, the packaging cell can be a stably transformed cancer cell, such as HeLa cell, 293 cell, and PerC.6 cell (similar 293 line).In another embodiment, the packaging cell is a cell that is not a transformed cancer cell, such as low-passage 293 cell (human fetal kidney cell transformed with adenovirus E1), MRC-5 cell (human fetal fibroblast), WI-38 cell (human fetal fibroblast), Vero cell (monkey kidney cell), and FRhL-2 cell (rhesus fetal lung cell).
[0086] As used herein, the recombinant AAV is a replication-deficient, infectious, encapsidated viral particle (rAAV) that comprises a rAAV genome. The rAAV encodes a therapeutic protein as described herein. The genome of the rAAV lacks the rep and cap DNA of AAV, i.e., there is no AAV rep or cap DNA between the ITRs of the rAAV genome.
[0087] rAAV can be purified by standard methods in the art, such as by column chromatography or cesium chloride gradients. Methods for purifying rAAV vectors from helper viruses are known in the art, including, for example, those disclosed in Clark et al., Hum. Gene Ther., 10(6): 1031-1039 (1999), Schenpp and Clark, Methods Mol. Med., 69: 427-443 (2002), U.S. Patent No. 6,566,118, and WO98 / 09657.
[0088] In another embodiment, the present invention contemplates a composition comprising the rAAV or therapeutic protein described herein. The composition of the present invention comprises the rAAV or therapeutic protein in a pharma- ceutically acceptable carrier. The composition may also include other components, such as diluents and adjuvants. Acceptable carriers, diluents, and adjuvants are non-toxic to recipients, preferably inert at the dosages and concentrations used, and include buffers such as phosphate, citrate, or other organic acids; antioxidants such as ascorbic acid; low molecular weight polypeptides; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or non-ionic surfactants such as Tween®, Pluronic®, or polyethylene glycol (PEG).
[0089] The titer of rAAV administered in the methods described herein will vary depending, for example, on the particular rAAV, the mode of administration, the therapeutic goal, the individual, and the cell type(s) being targeted, and can be determined by standard methods in the art. The titer of rAAV is approximately 1 x 10 per mL. 10 , about 1×10 11 , about 1×10 12 , about 1×10 13 ~Approx. 1×10 14 Dosages may range from 100 mg to 150 mg of DNase resistant particles (DRP) or greater. Dosages may be expressed in units of viral genomes (vg) as understood in the art.
[0090] Methods of transducing target cells with rAAV in vivo or in vitro are contemplated by the present invention. In vivo methods include administering an effective dose, or multiple effective doses, of a composition comprising an rAAV as described herein to an animal (including a human patient) in need thereof.
[0091] The dosage and frequency of administration of the therapeutic proteins described herein may vary depending on factors such as the route of administration, the particular therapeutic protein being administered, and the size and general condition of the patient. Appropriate dosages can be determined by procedures known in the relevant art, for example, in clinical trials that may involve dose escalation studies. Taking these factors into account, typical doses of the therapeutic proteins described herein may range from about 0.1 pg / kg up to about 30 mg / kg or more. Furthermore, doses may range from 0.1 pg / kg up to about 30 mg / kg, 1 pg / kg up to about 30 mg / kg, 10 pg / kg up to about 10 mg / kg, about 0.1 mg / kg to 5 mg / kg, or about 0.3 mg / kg to 3 mg / kg.
[0092] Accordingly, also provided is a method of treating a patient with a therapeutic protein described herein, comprising administering to an animal (including a human patient) in need thereof an effective dose, or multiple effective doses, of a composition comprising a therapeutic protein described herein.
[0093] When a dose is administered before the onset of a disorder / disease, the administration is prophylactic. When a dose is administered after the onset of a disorder / disease, the administration is therapeutic. An "effective dose" is a dose that alleviates (eliminates or reduces) at least one symptom associated with the disorder / disease state being treated, slows or prevents progression to the disorder / disease state, slows or prevents progression of the disorder / disease state, reduces the extent of the disease, causes remission (partial or complete) of the disease, and / or prolongs survival. The methods described herein result in one or more of improved walking time, limb grip strength, reduced muscle pathology, and reduced neuropathology in treated patients. Other endpoints achieved by the methods described herein are one or more of increased muscle fiber size, reduced small oxidative fiber number, correction of muscle atrophy, increased muscle strength, and increased muscle regeneration in treated patients. Dystroglycanopathies and laminin-deficient muscular dystrophies are contemplated for prevention or treatment by the methods of the present invention.
[0094] Combination therapy is also contemplated by the present invention. Combination therapy as used herein includes both simultaneous or sequential therapy. Combination of the methods described herein with standard drug therapy is particularly contemplated, as is combination with novel therapies.
[0095] Administration of an effective dose of a composition of rAAV or therapeutic protein may be by routes standard in the art, including, but not limited to, intramuscular, parenteral, intravenous, intrathecal, oral, buccal, nasal, pulmonary, intracranial, intraosseous, intraocular, rectal, or intravaginal. The route(s) of administration and serotype(s) of the AAV components of the rAAV of the present invention (specifically, the AAV ITRs and capsid proteins) may be selected and / or adapted by one skilled in the art taking into account the infection and / or disease state to be treated, and the target cell / tissue(s) expressing the therapeutic protein.
[0096] In particular, the actual administration of the rAAV of the present invention can be accomplished by using any physical method that delivers the rAAV recombinant vector to the target tissue of an animal. Administration according to the present invention includes, but is not limited to, injection into the muscle, injection into the bloodstream, and / or direct injection into the liver. Simply resuspending rAAV in phosphate buffered saline or lactated Ringer's solution has been demonstrated to be sufficient to provide a vehicle useful for muscle tissue expression, and there are no known limitations on the carriers or other components that may be co-administered with rAAV (although compositions that degrade DNA should be avoided in the usual manner with rAAV). The capsid protein of rAAV may be modified to target the rAAV to a specific target tissue of interest, such as muscle. See, for example, WO02 / 053703, the disclosure of which is incorporated herein by reference. The pharmaceutical composition can be prepared as an injectable formulation or as a local formulation that is delivered to muscle by transdermal delivery. Numerous formulations for both intramuscular injection and transdermal delivery have been developed to date and can be used in the practice of the present invention. The rAAV can be used with any pharma- ceutically acceptable carrier for ease of administration and handling.
[0097] For the purpose of intramuscular injection, solutions of rAAV or therapeutic protein in adjuvants such as sesame or peanut oil, or aqueous propylene glycol, as well as sterile aqueous solutions can be used. Such aqueous solutions can be buffered, if necessary, and the liquid diluent is first rendered isotonic with saline or glucose. Solutions of rAAV as a free acid (DNA contains acidic phosphate groups) or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions of rAAV can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof, as well as in oils. Under ordinary storage and use conditions, these formulations contain a preservative to prevent the growth of microorganisms. In this connection, all of the sterile aqueous media employed are readily available by standard techniques well known to those skilled in the art.
[0098] Pharmaceutical forms of rAAV or therapeutic proteins suitable for systemic (e.g., intravenous) injection use include sterile aqueous solutions or dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be, for example, a solvent or dispersion medium containing water, ethanol, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. Proper fluidity can be maintained, for example, by the use of a coating agent such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include an isotonic agent, for example, sugar or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0099] Sterile injectable solution is prepared by incorporating the required amount of rAAV into a suitable solvent, and then sterilizing by filtration, with various other components as listed above as necessary.Generally, dispersion is prepared by mixing sterilized active ingredient into a sterile vehicle that contains basic dispersion medium and other required components from those listed above.In the case of sterile powder for preparing sterile injectable solution, the preferred preparation method is vacuum drying and freeze-drying technology, which produces powder of active ingredient and any additional desired components from the solution that has been previously sterilized and filtered.
[0100] Transduction with rAAV can also be performed in vitro. In one embodiment, the desired target muscle cells are removed from the subject, transduced with rAAV, and reintroduced into the subject. Alternatively, syngeneic or xenogeneic muscle cells can be used if they do not generate an inappropriate immune response in the subject.
[0101] Suitable methods for transduction and reintroduction of transduced cells into a subject are known in the art. In one embodiment, cells can be transduced in vitro, for example by combining rAAV with muscle cells in a suitable medium and screening for cells with the DNA of interest using conventional techniques such as Southern blot and / or PCR, or using a selectable marker. The transduced cells can then be formulated into a pharmaceutical composition, and the composition can be introduced into a subject by a variety of techniques, such as by intramuscular, intravenous, subcutaneous, and intraperitoneal injection, or by injection into smooth and cardiac muscles, for example, using a catheter.
[0102] Transduction of cells with the rAAV of the invention results in sustained expression of the therapeutic proteins described herein. Thus, the invention provides methods for administering rAAV expressing the therapeutic proteins described herein to a patient, preferably a human. These methods include transducing one or more rAAV of the invention into tissues, including, but not limited to, tissues such as muscle, organs such as liver and brain, and glands such as salivary glands.
[0103] Because muscle tissue is not a vital organ and is easily accessible, it is an attractive target for in vivo DNA delivery. The present invention contemplates sustained expression of the therapeutic proteins described herein from transduced muscle cells.
[0104] By "muscle cell" or "muscle tissue" is meant a cell or group of cells derived from any type of muscle, such as skeletal muscle and smooth muscle (e.g., gastrointestinal, bladder, blood vessels, or heart tissue). Such muscle cells can be differentiated or undifferentiated, such as myoblasts, myocytes, myotubes, cardiomyocytes, and cardiomyoblasts.
[0105] The term "transduction" is used to refer to the administration / delivery of a therapeutic protein to a recipient cell, either in vivo or in vitro, via the rAAV of the present invention, resulting in expression of the therapeutic protein by the recipient cell.
[0106] Thus, provided herein are methods of administering an effective dose (or doses administered essentially simultaneously or at intervals) of a rAAV encoding a therapeutic protein described herein to a patient in need thereof.
[0107] Also provided herein are methods of administering an effective dose (or doses administered essentially simultaneously or at intervals) of a therapeutic protein described herein to a patient in need thereof. EXAMPLES
[0108] Aspects and embodiments of the present invention are illustrated by the following examples. Example 1 describes constructs encoding therapeutic proteins of the present disclosure. Example 2 describes recombinant expression of therapeutic proteins in cultured host cells. Example 3 describes experiments demonstrating that the heparin-binding domain targets LAMA2 (g1-G50) to muscle in wild-type mice. Example 4 describes the dysregulation of MDC1A. W / dy W Experiments are described to demonstrate the effectiveness of AAV-mediated HBEGF-LAMA2 (G1-5) expression in reducing symptoms and pathology in a mouse model. Example 5 describes experiments to demonstrate the effectiveness of AAV-mediated HBEGF-DAG1 (α) expression in reducing symptoms and pathology in a mouse model of dystroglycanopathy. Example 6 describes the properties of sHBEGF (domains) contemplated herein to be useful for its application as a linker domain in therapeutic proteins described herein and as a nutrient in various methods described herein.
[0109] Example 1 Constructs encoding therapeutic proteins Six exemplary DNA constructs encoding therapeutic proteins containing the HBEGF EGF domain were generated as follows: HB-EGF (ending in the heparin-binding domain)-LAMA2 G1-G5 (encoded by the polynucleotide of FIG. 3 ); HB-EGF (fully soluble)-LAMA2 G1-G5 (encoded by the polynucleotide of FIG. 4 ); HB-EGF (ending in the heparin binding domain)-LAMA2 G3-G5 (encoded by the polynucleotide of FIG. 5 ); HB-EGF (fully soluble)-LAMA2 G3-G5 (encoded by the polynucleotide of FIG. 6); HB-EGF (ending in the heparin binding domain)-DAG1 (the native processed alpha-DG gene) (encoded by the polynucleotide of FIG. 7), and HB-EGF (intact soluble)-DAG1 (native processed alpha-DG gene) (encoded by the polynucleotide of FIG. 8).
[0110] The constructs were expressed from plasmids in CHO cells, which were either transfected with a plasmid containing one of the constructs or mock transfected (-).
[0111] Transfected CHO cells were stained with antibodies against HB-EGF, dystroglycan, or laminin-α2 G5 domain. The results are shown in Figure 9A. Culture medium was also collected from each plate 48 hours after transfection and cell lysis was performed. Heparin-agarose pull-down was performed on both cell lysates and culture medium, which were loaded onto Western blots along with the whole cell lysates. The results are shown in Figure 9B.
[0112] Example 2 Recombinant expression of therapeutic proteins in cultured host cells The constructs of Example 1 were also subcloned into plasmids to generate AAV9 vectors encoding therapeutic proteins.
[0113] An AAV vector was generated carrying one of the therapeutic genes of Example 1 under the transcriptional control of the cytomegalovirus (CMV) promoter.
[0114] rAAV vectors were generated by a modified cross-packaging approach that allows packaging of AAV type 2 vector genomes into multiple AAV capsid serotypes [Rabinowitz et al., J Virol. 76(2):791-801(2002)]. Generation was achieved using a standard three-plasmid DNA / CaPO4 precipitation method using HEK293 cells. HEK293 cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and penicillin and streptomycin. The generation plasmids were (i) plasmids encoding therapeutic proteins, (ii) a rep2-capX modified AAV helper plasmid encoding a cap serotype 9 isolate, and (iii) an adenovirus type 5 helper plasmid (pAdhelper) expressing adenovirus E2A, E4 ORF6, and VA I / II RNA genes. A quantitative PCR-based titration method was used to determine encapsidated vector genome (vg) titers utilizing a Prism 7500 Taqman detector system (PE Applied Biosystems) [Clark et al., Hum Gene Ther. 10(6):1031-1039(1999)]. Final titers (vgml -1 ) was determined by quantitative reverse transcriptase PCR using specific primers and probes utilizing a Prism 7500 real-time detector system (PE Applied Biosystems, Grand Island, NY, USA). Split viruses were stored at −80°C until use.
[0115] The rAAVs shown in Table 2 were used in the experiments described herein. [Table 2]
[0116] Example 3 The heparin-binding domain targets LAMA2(G1-G5) to muscle in wild-type mice Wild-type mice were cultured with 5x10 IgG containing HBEGF, HBEGF.LAMA2(G1-G5), HBEGF.LAMA2(G3-G5), HB.LAMA2(G1-G5), HB.LAMA2(G3-G5), or LAMA2(G1-G5) (see Table 2). 11 vg pf rAAV9.CMV vector was injected intramuscularly into the gastrocnemius muscle. Cells were stained with antibodies specific for human HB-EGF or recombinant G5 domain of LAMA2. Mock-injected mice (buffer only) are shown as negative controls. 4H8-2 is an anti-laminin antibody that shows muscle cells in sections.
[0117] As shown in FIG. 15, previously shown for overexpression of HBEGF, HBEGF and HBEGF.LAMA2(G1-G5) reduced muscle growth and / or induced mild muscle atrophy, whereas IM injection of rAAV9.CMV.HB.LAMA2(G1-G5) leads to secretion and localization of LAMA2(G1-G5) protein in the extracellular matrix. In addition, muscles expressing HB.LAMA2(G1-G5) appeared to be larger than normal wild-type muscles. HB.LAMA2(G3-G5) showed lower overall protein staining than HB.LAMA2(G1-G5). The ECM targeting function of the HB domain of HBEGF allows for secretion and targeting of LAMA2(G1-G5) protein to the muscle extracellular matrix. In contrast, expression of LAMA2(G1-G5) without the HB domain resulted in very low protein production and no detectable ECM localization. Thus, a construct containing only the HB domain, rather than the complete HB-EGF domain, serves the purpose of targeting LAMA2 (G1-G5) to muscle ECM, and since this construct has the EGF domain deleted from HBEGF, it does so without adversely affecting EGF signaling.
[0118] The prepropeptide portion of HBEGF still present in the HB construct may also improve protein folding and / or expression of LAMA2(G1-G5) compared to LAMA2(G1-G5) alone, which contains only the signal peptide from HBEGF. Finally, HB.LAMA2(G1-G5), when properly localized, may also improve muscle growth in normal muscle.
[0119] Figure 16 shows staining of HBEGF.LAMA2(G1-G5), HB.LAMA2(G1-G5), and LAMA2(G1-G5) using antibodies against human HBEGF protein and against the G5 domain of human LAMA2. The data confirm that expression of LAMA2(G1-G5) alone greatly reduces protein production in muscle, while inclusion of the HB domain improves expression of LAMA2(G1-G5), which was visualized with anti-laminin and HBEGF antibodies.
[0120] Example 4 MDC1A dy W / dy W Efficacy of AAV9-mediated HBEGF-LAMA2(G1-5) expression in reducing symptoms and pathology in a mouse model dy W / dy W Mice [Nonaka, Lab Anim Sci., 48(1):8-17(1998)] have a loss-of-function mutation in Lama2, which leads to impaired laminin-α2 synthesis, similar to the pathology of MDC1A. W / dy W MDC1A mice have reduced size, grip strength, and lifespan compared to wild-type mice. Mice exhibit muscle atrophy, dystrophic muscle pathology, and severe gait disorders by 3 months of age. Therefore, these mice are a suitable and robust model for testing MDC1A therapies.
[0121] To demonstrate the therapeutic effect of the LAMA2-expressing rAAV genome provided in Example 2, eight dystrophin-positive mice were incubated at 1 day after birth. W / dy W A low dose of 10 11 viral genome (vg) or high doses of 10 12 vg, rAAV9.CMV.HBEGF.LAMA2(G1-G5), rAAV9.CMV.HB.LAMA2(G1-G5), or rAAV.CMV.HB.LAMA2(G3-G5) were injected intravenously via the facial vein. W / dy W Sham injections of AAV buffer were also performed on pups.
[0122] Grip strength of the forelimb muscles was analyzed at 2 and 3 months after injection (Figure 17). At 4 months of age, mice were euthanized and limb muscles were dissected and analyzed for recombinant protein expression. As shown in Figure 17, both HB.LAMA2(G3-G5) and HB.LAMA2(G1-G5) prevented the decline in grip strength in dy / dy mice, showing a significant change from sham-treated dy / dy mice and bringing strength values within the range seen in untreated wild-type mice of the same age. Thus, both HB-LAMA2(G3-G5) and HB-LAMA2(G1-G5) show therapeutic efficacy in the dy / dy model of MDC1A. In this experiment, HB.LAMA2(G3-G5) did not reach significance at 2 months compared to sham-treated dy / dy mice, whereas HB.LAMA2(G1-G5) did.
[0123] The role of transgene expression in preventing muscle pathology was also analyzed by comparing the percentage of myofibers with central nuclei, myofiber diameter and area, and variation in myofiber diameter in treated dy / dy mice. Triceps muscles were used to compare muscle pathology in transgene-expressing myofibers with the same pathology measurements in non-expressing myofibers. This experiment demonstrated that expression of HB.LAMA2(G1-G5) increases muscle size. Examples of staining showing such changes are shown in Figure 18. When quantified across all muscles, the average transverse muscle area was 2328 mm for expressing myofibers, 100% for non-expressing myofibers, and 100% for non-expressing myofibers. 2 vs. 1082mm for non-expressing muscle fibers 2 (n=4 muscles, 400 myofibers per muscle analyzed each), which was a 2-fold average increase in muscle size with treatment. The variance of myofiber diameter index (diameter SD / mean x 1000) decreased from 620 in non-expressing muscles to 431 in expressing muscles (250 or less is considered normal), and the percentage of myofibers with central nuclei, an indicator of cycles of muscle degeneration and regeneration, decreased from 28% in non-expressing muscles to 14% in expressing muscles (n=2 each).
[0124] It is important to remember that while pathology is never reduced to zero, it takes 3-4 weeks for AAV to achieve maximal gene expression, so in these animals some degree of pathology will develop before any expression of the therapeutic transgene occurs. In all such experiments, the average level of muscle conversion was 26 ± 1% (n = 4 triceps muscles analyzed, 400 fibers each). What we get from these pathological measurements is that HB-LAMA2(G1-G5) appears to not only prevent, at least in part, muscle damage in dy / dy muscles, but also revert to wild type, and possibly increase muscle growth beyond that.
[0125] Example 5 Efficacy of AAV-mediated HBEGF-DAG1(α) expression in reducing symptoms and pathology in a mouse model of dystroglycanopathy Mice lacking dystroglycan or fukutin, the α-dystroglycan glycosylating enzyme encoded by the Fktn gene, are embryonic lethal and cannot be used to study dystroglycanopathy therapies. loxP The efficacy will be demonstrated using mice [Kanagawa et al., Hum Mol Genet., 22(15):3003-3015(2013)]. loxP The mice have reduced body weight, grip strength, and life span compared to wild-type mice, and also display dystrophic muscle pathology.
[0126] Myf5Cre-Fktn loxP To demonstrate the therapeutic effect of rAAV9.CMV.HBEGF-DAG1(α) in a mouse model, the same injection protocol and evaluation as described in Example 3 will be performed.
[0127] Another mouse model of dystroglycanopathy is the Large-vls mouse mutant (Lee et al., Mol. Cell. Neurosci. 30:160-172, 2005). Some Large-vls mice were injected with 1 × 1012 vg rAAV9.CMV.HB-DAG1IV was injected IM. Grip strength testing of these mice suggests potential improvement. Among 4–7 animals analyzed per group at 2 months, forelimb grip strength decreased from 4.7 ± .2 g / g in wild type to 3.8 ± 0.1 g / g in untreated Large vls mice (p=0.0005), whereas pAAV9.CMV.HB-DAG1(α)-treated Large vls mice (1 × 10 at P1) showed a significant improvement. 12 vls IV) showed that grip strength improved to 4.4 ± .3 g / g (p = .06 vs. sham-treated Large vls). This data was very close to significance and it is possible that significance could be achieved with additional measurements.
[0128] Example 6 sHBEGF and nutrients as linker proteins The use of the heparin-binding domain and EGF-like domain of soluble HBEGF (sHBEGF) in various exemplary therapeutic proteins described herein provides a dual benefit to patients. The inclusion of both domains increases muscle membrane stability with the inclusion of the heparin-binding domain along with LAMA2 (G1-5) or DAG1 (α), while the inclusion of the EGF-like domain further stimulates muscle regeneration. Figures 10, 11, and 12 show that sHBEGF activates the Akt kinase pathway in muscle and increases the expression of muscle regeneration markers. Expression of activated Akt kinase in muscle has previously been shown to stimulate significant muscle growth, similar to that seen with myostatin inhibitors. Thus, the presence of the EGF-like domain of HBEGF in various therapeutic proteins described herein adds an additional therapeutic benefit to the treatment of diseases described herein.
[0129] Inject 5 × 10 insulin into the left gastrocnemius muscle of 5-week-old male C57BL / 6J mice, near the midpoint of the muscle, using a 0.3 mL insulin syringe in a volume of 50 µL of sterile PBS. 10The vector genomes r(ds)AAV9.CMV.HB-EGF or r(ds)AAV9.CMV.sHB-EGF were injected. The contralateral (right) muscle of the mice was sham-injected with an equal volume of sterile PBS. Four or 12 weeks after injection, the mice were sacrificed and dissected. The gastrocnemius muscles were embedded in OCT compound (Fisher Scientific, Pittsburgh, PA) and flash-frozen in liquid nitrogen-cooled isopentane.
[0130] Expression of sHB-EGF was visualized using an antibody that recognizes sHB-EGF and co-stained with either an antibody against Galgt2 protein or CT glycan. sHB-EGF was expressed along the sarcolemma of skeletal muscle fibers in muscles analyzed 4 weeks after injection of r(ds)AAV9.CMV.sHB-EGF. Figure 9 shows that sHB-EGF can be secreted from muscle and attached to the extracellular matrix, supporting its use as a linker protein.
[0131] FIG. 10 shows that sHB-EGF induces expression of therapeutic surrogate muscular dystrophy genes.
[0132] FIG. 11 shows that sHB-EGF can induce the Akt tyrosine kinase cascade in skeletal muscle and stimulate muscle growth and regeneration.
[0133] While the invention has been described with respect to specific embodiments, it is understood that variations and modifications will occur to those skilled in the art, and therefore only such limitations as appear in the claims should be placed on the invention.
[0134] All documents referenced in this application are incorporated herein by reference in their entirety. The present invention provides, for example, the following items. (Item 1) a) a first domain comprising the heparin-binding domain of heparin-binding epidermal growth factor-like growth factor (HBEGF) and a second domain comprising the G1-G5 domain of the human laminin alpha 2 (LAMA2) gene; b) a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising the G1-G5 domain of the human LAMA2 gene; c) a first domain comprising the heparin-binding domain of HBEGF and a second domain comprising the G3-G5 domain of the human LAMA2 gene; or d) A polynucleotide encoding a protein comprising a first domain comprising the heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising the G3-G5 domain of the human LAMA2 gene. (Item 2) 2. The polynucleotide of item 1, wherein the first domain of the protein is encoded by the nucleotide sequence of SEQ ID NO: 13 or SEQ ID NO: 14. (Item 3) 3. The polynucleotide according to item 1 or 2, wherein the second domain of the protein is encoded by the nucleotide sequence of SEQ ID NO: 15 or SEQ ID NO: 16. (Item 4) 4. The polynucleotide according to any one of items 1 to 3, wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 13 and SEQ ID NO: 15. (Item 5) 4. The polynucleotide according to any one of items 1 to 3, wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 13 and SEQ ID NO: 16. (Item 6) 4. The polynucleotide according to any one of items 1 to 3, wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 14 and SEQ ID NO: 15. (Item 7) 4. The polynucleotide according to any one of items 1 to 3, wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 14 and SEQ ID NO: 16. (Item 8) The polynucleotide according to item 1(a), comprising i) nucleotides 14 to 3235 shown in FIG. 3, ii) the nucleotide sequence of SEQ ID NO: 1, or iii) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 19. (Item 9) The polynucleotide according to item 1(b), comprising i) nucleotides 14 to 3361 shown in FIG. 4, ii) the nucleotide sequence of SEQ ID NO: 3, or iii) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 20. (Item 10) The polynucleotide according to item 1(c), comprising i) nucleotides 14 to 1930 shown in FIG. 5, ii) the nucleotide sequence of SEQ ID NO: 5, or iii) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 21. (Item 11) i) the nucleotide sequence of nucleotides 14 to 2056 shown in FIG. 6, SEQ ID NO: 7; or iii) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 22. (Item 12) 12. A recombinant adeno-associated virus (rAAV), wherein the genome of the rAAV comprises the polynucleotide according to any one of items 1 to 11. (Item 13) A recombinant adeno-associated virus (rAAV), wherein the genome of the rAAV comprises the polynucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7. (Item 14) The rAAV of item 12 or 13, wherein the genome of the rAAV further comprises a muscle-specific transcriptional regulatory element. (Item 15) The rAAV of item 14, wherein the muscle-specific transcriptional regulator is a CMV promoter. (Item 16) A recombinant adeno-associated virus (rAAV), wherein the genome of the rAAV comprises nucleotides 3590 to 8215 of SEQ ID NO:2, nucleotides 3590 to 8341 of SEQ ID NO:4, nucleotides 3609 to 6929 of SEQ ID NO:6, nucleotides 3590 to 7036 of SEQ ID NO:8, or a nucleotide sequence set forth in FIG. 13. (Item 17) 17. The rAAV of any one of items 12 to 16, comprising an AAV9, AAV10, AAVrh74, AAV8, or AAV6 capsid. (Item 18) An rAAV particle comprising the rAAV described in any one of items 12 to 17. (Item 19) A recombinant host cell comprising the polynucleotide according to any one of items 1 to 11. (Item 20) 20. The host cell according to item 19, which is a Chinese hamster ovary (CHO) cell or a HEK293 cell. (Item 21) A protein encoded by the polynucleotide according to any one of items 1 to 11. (Item 22) A protein comprising the amino acid sequence of SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22. (Item 23) A composition comprising a polynucleotide described in any one of items 1 to 11, an rAAV described in any one of items 12 to 17, an rAAV particle described in item 18, or a protein described in item 21 or 22. (Item 24) A method for treating laminin-deficient muscular dystrophy, comprising administering to a patient in need of said treatment a polynucleotide according to any one of items 1 to 11, a polynucleotide according to any one of items 12 to 17, or a polypeptide according to any one of items 13 to 18. 25. A method comprising administering an rAAV as described in claim 14, an rAAV particle as described in claim 18, a protein as described in claim 21 or 22, or a composition as described in claim 23. (Item 25) 23. A composition for use in treating a laminin-deficient muscular dystrophy in a patient in need of treatment, the composition comprising the polynucleotide of any one of items 1 to 11, the rAAV of any one of items 12 to 17, the rAAV particle of item 18, the protein of item 21 or 22, or the composition of item 23. (Item 26) Use of a polynucleotide according to any one of items 1 to 11, an rAAV according to any one of items 12 to 17, an rAAV particle according to item 18, a protein according to item 21 or 22, or a composition according to item 23 for the preparation of a medicament for the treatment of laminin-deficient muscular dystrophy. (Item 27) 27. The method, composition, or use according to any one of items 24 to 26, wherein the laminin-deficient muscular dystrophy is MDC1A. (Item 28) a) a first domain comprising the heparin-binding domain of HBEGF and a second domain comprising the processed native alpha chain (DAG1 alpha) of the human dystroglycan gene; or b) a polynucleotide encoding a protein comprising a first domain comprising said heparin-binding domain of HBEGF and the EGF-like domain of HBEGF, and a second domain comprising DAG1 alpha. (Item 29) 29. The polynucleotide of item 28, wherein the first domain of the protein is encoded by the nucleotide sequence of SEQ ID NO: 13 or SEQ ID NO: 14. (Item 30) 30. The polynucleotide according to item 28 or 29, wherein the second domain of the protein is encoded by the nucleotide sequence of SEQ ID NO: 17. (Item 31) 31. The polynucleotide according to any one of items 28 to 30, wherein the polypeptide comprises the nucleotide sequence of SEQ ID NO: 13 and SEQ ID NO: 17. (Item 32) 31. The polynucleotide according to any one of items 28 to 30, wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 14 and SEQ ID NO: 17. (Item 33) 28. The polynucleotide according to claim 28(a), comprising: i) nucleotides 14 to 1360 shown in FIG. 7; ii) the nucleotide sequence of SEQ ID NO: 9; or iii) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 23. (Item 34) 28(b), comprising i) a nucleotide sequence encoding nucleotides 14 to 1486 shown in FIG. 8, ii) a nucleotide sequence of SEQ ID NO: 11, or iii) an amino acid sequence of SEQ ID NO: 24. (Item 35) A recombinant adeno-associated virus (rAAV), wherein the genome of the rAAV comprises the polynucleotide according to any one of items 28 to 34. (Item 36) A recombinant adeno-associated virus (rAAV), wherein the genome of the rAAV comprises the polynucleotide sequence of SEQ ID NO:9 or SEQ ID NO:11. (rAAV). (Item 37) 37. The rAAV of claim 35 or 36, wherein the genome of the rAAV further comprises a muscle-specific transcriptional regulatory element. (Item 38) 38. The rAAV of claim 37, wherein the muscle-specific transcriptional regulator is a CMV promoter. (Item 39) A recombinant adeno-associated virus (rAAV), wherein the genome of the rAAV comprises nucleotides 3590 to 6340 of SEQ ID NO: 10, nucleotides 3590 to 6049 of SEQ ID NO: 12, or a nucleotide sequence set forth in FIG. 14. (Item 40) 40. The rAAV of any one of paragraphs 35 to 39, comprising an AAV9, AAV10, AAVrh74, AAV8, or AAV6 capsid. (Item 41) An rAAV particle comprising the rAAV described in any one of items 35 to 40. (Item 42) A recombinant host cell comprising the polynucleotide according to any one of items 28 to 34. (Item 43) 43. The host cell according to item 42, which is a Chinese hamster ovary (CHO) cell or a HEK293 cell. (Item 44) A protein encoded by the polynucleotide according to any one of items 28 to 34. (Item 45) A protein comprising the amino acid sequence of SEQ ID NO:23 or SEQ ID NO:25. (Item 46) A composition comprising a polynucleotide described in any one of items 28 to 34, an rAAV described in any one of items 35 to 40, an rAAV particle described in item 41, or a protein described in item 44 or 45. (Item 47) A method for treating dystroglycanopathy, comprising administering to a patient in need of said treatment a polynucleotide according to any one of items 28 to 34, an rAAV according to any one of items 35 to 40, an rAAV particle according to item 41, a protein according to item 44 or 45, or a composition according to item 46. (Item 48) 47. A composition for use in treating a dystroglycanopathy in a patient in need of treatment, the composition comprising a polynucleotide according to any one of items 28 to 34, an rAAV according to any one of items 35 to 40, an rAAV particle according to item 41, a protein according to item 44 or 45, or a composition according to item 46. (Item 49) Use of a polynucleotide according to any one of items 28 to 34, an rAAV according to any one of items 35 to 40, an rAAV particle according to item 41, a protein according to item 44 or 45, or a composition according to item 46 for the preparation of a medicament for the treatment of dystroglycanopathy. (Item 50) The dystroglycanopathy is Walker-Warburg syndrome, myo-oculo-encephalopathy, Fukuyama type 50. The method, composition or use according to any one of items 47 to 49, wherein the congenital muscular dystrophy is MDC1C, MDC1D, LGMD2I, LGMD2K, LGMD2M, LGMD2N, LGMD2O, LGMD2P, LGMD2T, or LGMD2U.
Claims
[Claim 1] The invention described in this specification.
Citation Information
Patent Citations
Alpha-dystroglycan as a Protein Therapeutic
US20110166081A1
Methods and materials for galgt2 gene therapy
WO2017049031A1
Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy
WO2017181015A1
